Evaluating the clinical trends and benefits of low-dose computed tomography in lung cancer patients.
Edmund M QiaoRohith S VooraVinit NalawadeNikhil V KothaAlexander S QianTyler J NelsonMichael DurkinLucas K VitzthumJames D MurphyTyler F StewartBrent S RosePublished in: Cancer medicine (2021)
Utilization of LDCT screening is increasing, although remains low. Consistent with randomized data, LDCT-screened patients were diagnosed at earlier stages and had lower CSM. LDCT availability appeared to be the main predictor of utilization. Providing access to more patients, including those in diverse racial and socioeconomic groups, should be a priority.
Keyphrases
- computed tomography
- end stage renal disease
- low dose
- newly diagnosed
- ejection fraction
- magnetic resonance imaging
- magnetic resonance
- randomized controlled trial
- high dose
- open label
- patient reported outcomes
- machine learning
- patient reported
- electronic health record
- african american
- study protocol
- placebo controlled